Suppr超能文献

1-(2-氯乙基)-3-环己基-1-亚硝基脲(CCNU)诱导肝毒性的机制研究。II. 损伤的生化和形态学特征以及苯巴比妥对其的预防作用

Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. II. Biochemical and morphological characterization of the injury and its prevention by phenobarbital.

作者信息

Ahmed A E, Grissom M, el-Azhary R, Haque A, Boor P J, Costanzi J

出版信息

Cancer Chemother Pharmacol. 1987;19(2):103-8. doi: 10.1007/BF00254560.

Abstract

The present study characterizes the biochemical, morphological, and histological sites of CCNU-induced hepatotoxicity and investigates the effect of modifiers of drug metabolism on this toxicity. A single oral dose (100 mg/kg) of CCNU caused four- and ninefold increases in serum GOT and GPT respectively 48 h after administration in rats. A 25-fold rise in serum bilirubin, a total loss of bile flow, and a decrease in BSP clearance were also observed. Cytochrome P-450 content and EM-N-demethylase activity were significantly decreased to 88% and 66% of control values respectively. A histopathological time course study of CCNU-induced injury showed a progression of acute inflammation, edema, and fibrin deposition in portal areas over 24 h with necrosis and sloughing of bile duct epithelium at 24 and 36 h. Treatment of rats with PB (40 mg/kg/day for 4 days, i.p.) 24 h prior to CCNU administration protected against CCNU-induced hepatotoxicity. Thus, the levels of serum GOT, GPT, and bilirubin were only 2.5 and 4 times higher than in untreated or PB-treated controls. Histopathological examination also showed reduced severity of bile duct lesions in PB-pretreated animals. In rats receiving both PB and CCNU, bile flow was restored and BSP clearance was increased compared to the CCNU-treated rats. The mixed-function oxidase activity in PB + CCNU-treated rats was not significantly different from that in PB-treated controls. It is concluded that pretreatment of rats with PB can markedly suppress the hepatotoxic manifestations, including histopathological changes, the rise in serum bilirubin, and the cholestasis observed in CCNU-treated rats.

摘要

本研究对洛莫司汀诱导肝毒性的生化、形态学和组织学部位进行了表征,并研究了药物代谢调节剂对这种毒性的影响。大鼠口服单次剂量(100mg/kg)的洛莫司汀后48小时,血清谷草转氨酶(GOT)和谷丙转氨酶(GPT)分别升高了4倍和9倍。还观察到血清胆红素升高了25倍、胆汁流量完全丧失以及磺溴酞钠(BSP)清除率降低。细胞色素P-450含量和乙氧甲酰基吗啡N-脱甲基酶活性分别显著降低至对照值的88%和66%。对洛莫司汀诱导损伤的组织病理学时间进程研究显示,在24小时内门静脉区急性炎症、水肿和纤维蛋白沉积逐渐加重,在24小时和36小时出现胆管上皮坏死和脱落。在给予洛莫司汀前24小时用苯巴比妥(PB,40mg/kg/天,腹腔注射,共4天)处理大鼠,可预防洛莫司汀诱导的肝毒性。因此,血清GOT、GPT和胆红素水平仅比未处理或PB处理的对照组高2.5倍和4倍。组织病理学检查还显示,PB预处理动物的胆管病变严重程度降低。与洛莫司汀处理的大鼠相比,同时接受PB和洛莫司汀的大鼠胆汁流量恢复,BSP清除率增加。PB + 洛莫司汀处理大鼠的混合功能氧化酶活性与PB处理对照组无显著差异。得出的结论是,用PB预处理大鼠可显著抑制肝毒性表现,包括组织病理学变化、血清胆红素升高以及在洛莫司汀处理大鼠中观察到的胆汁淤积。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验